Literature DB >> 10898511

A role for IL-5 in the induction of cytotoxic T lymphocytes in vivo.

V Apostolopoulos1, I F McKenzie, C Lees, K I Matthaei, I G Young.   

Abstract

IL-5 is generally regarded as a Th2 cytokine involved in eosinophil maturation and function and in B cell growth and antibody production, but without any well-established effects on T cells. Early reports suggested that IL-5 could stimulate the production of cytotoxic T lymphocytes (CTL) in vitro, but no evidence has been obtained to date for such a role in studies with IL-5-deficient (IL-5-/-) mice. Here we demonstrate that when oxidized mannan MUC1 fusion protein (M-FP) is used as an antigen in mice, IL-5 is required for the optimal generation of the CTL response. IL-5 was as effective as IL-2 for the induction of CTL from spleen cells in vitro and both CD4+ and CD8+ T cells from M-FP-immunized animals could be shown to secrete IL-5 in culture. In IL-5-/- mice, CTLp frequency was greatly diminished resulting in the inability to reject MUC1- tumors. Clearly, IL-5 is produced by functional T cells, especially the Tc1 type, after M-FP immunization and is required for an optimal CTL response to this antigen.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10898511     DOI: 10.1002/1521-4141(200006)30:6<1733::AID-IMMU1733>3.0.CO;2-E

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: a prospective study.

Authors:  Yian Gu; Roy E Shore; Alan A Arslan; Karen L Koenig; Mengling Liu; Sherif Ibrahim; Anna E Lokshin; Anne Zeleniuch-Jacquotte
Journal:  Cancer Causes Control       Date:  2010-04-07       Impact factor: 2.506

2.  Alveolar macrophage function is altered in patients with lung cancer.

Authors:  D S Pouniotis; M Plebanski; V Apostolopoulos; C F McDonald
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

3.  Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells.

Authors:  Kuo-Ching Sheng; Dodie S Pouniotis; Mark D Wright; Choon Kit Tang; Eliada Lazoura; Geoffrey A Pietersz; Vasso Apostolopoulos
Journal:  Immunology       Date:  2006-07       Impact factor: 7.397

4.  Regulation of IFN-gamma signaling is essential for the cytotoxic activity of CD8(+) T cells.

Authors:  G Z Tau; S N Cowan; J Weisburg; N S Braunstein; P B Rothman
Journal:  J Immunol       Date:  2001-11-15       Impact factor: 5.422

5.  Persistence of Integrase-Deficient Lentiviral Vectors Correlates with the Induction of STING-Independent CD8+ T Cell Responses.

Authors:  Céline Cousin; Marine Oberkampf; Tristan Felix; Pierre Rosenbaum; Robert Weil; Sylvie Fabrega; Valeria Morante; Donatella Negri; Andrea Cara; Gilles Dadaglio; Claude Leclerc
Journal:  Cell Rep       Date:  2019-01-29       Impact factor: 9.423

6.  Monitoring of CD4+ and CD8+ T-cell responses after dendritic cell-based immunotherapy using CFSE dye dilution analysis.

Authors:  Thomas Putz; Reinhold Ramoner; Hubert Gander; Andrea Rahm; Georg Bartsch; Lorenz Höltl; Martin Thurnher
Journal:  J Clin Immunol       Date:  2004-11       Impact factor: 8.317

7.  Double positive CD4CD8 alphabeta T cells: a new tumor-reactive population in human melanomas.

Authors:  Juliette Desfrançois; Agnès Moreau-Aubry; Virginie Vignard; Yann Godet; Amir Khammari; Brigitte Dréno; Francine Jotereau; Nadine Gervois
Journal:  PLoS One       Date:  2010-01-05       Impact factor: 3.240

8.  Anti-drug Antibodies Against a Novel Humanized Anti-CD20 Antibody Impair Its Therapeutic Effect on Primary Biliary Cholangitis in Human CD20- and FcγR-Expressing Mice.

Authors:  Yuki Moritoki; Koichi Tsuneyama; Yuka Nakamura; Kentaro Kikuchi; Akira Shiota; Yoshiyuki Ohsugi; Zhe-Xiong Lian; Weici Zhang; Guo-Xiang Yang; Shigeharu Ueki; Masahide Takeda; Ayumi Omokawa; Tomoo Saga; Akiko Saga; Daisuke Watanabe; Masahito Miura; Yoshiyuki Ueno; Patrick S C Leung; Atsushi Tanaka; M Eric Gershwin; Makoto Hirokawa
Journal:  Front Immunol       Date:  2018-11-02       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.